CytoMed Therapeutics Valuation
| GDTC Stock | 2.55 0.17 7.14% |
Based on Macroaxis valuation methodology, the firm appears to be undervalued. CytoMed Therapeutics shows a prevailing Real Value of USD3.09 per share. The current price of the firm is USD2.55. Our model approximates the value of CytoMed Therapeutics from analyzing the firm fundamentals such as Operating Margin of (7.36) %, shares outstanding of 11.54 M, and Return On Equity of -0.26 as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting CytoMed Therapeutics' valuation include:
Undervalued
Today
Please note that CytoMed Therapeutics' price fluctuation is dangerous at this time. Calculation of the real value of CytoMed Therapeutics is based on 3 months time horizon. Increasing CytoMed Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since CytoMed Therapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of CytoMed Stock. However, CytoMed Therapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 2.55 | Real 3.09 | Target 5.0 | Hype 2.45 |
The real value of CytoMed Stock, also known as its intrinsic value, is the underlying worth of CytoMed Therapeutics Company, which is reflected in its stock price. It is based on CytoMed Therapeutics' financial performance, growth prospects, management team, or industry conditions. The intrinsic value of CytoMed Therapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of CytoMed Therapeutics Limited helps investors to forecast how CytoMed stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of CytoMed Therapeutics more accurately as focusing exclusively on CytoMed Therapeutics' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use CytoMed Therapeutics' intrinsic value based on its ongoing forecasts of CytoMed Therapeutics' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against CytoMed Therapeutics' closest peers. If more than one evaluation category is relevant for CytoMed Therapeutics we suggest using both methods to arrive at a better estimate.
CytoMed Therapeutics Cash |
|
CytoMed Valuation Drivers Correlation
Many accounts on the financial statements of CytoMed Therapeutics are highly interrelated and sometimes correlated. Consequently, when conducting CytoMed's valuation analysis, one should examine all of the accounts reported to obtain a complete picture of its financial situation. We provide a unique feature to present a conventional correlation table purposely composed against different valuation-related drivers of CytoMed
Click cells to compare fundamentals
CytoMed Valuation Trend
Comparing CytoMed Therapeutics' enterprise value against its market capitalization is a good way to estimate the value of CytoMed Therapeutics Limited uage its performance over time. This information may sometimes be enough for investors to make reasonable market timing decisions.
CytoMed Therapeutics Total Value Analysis
CytoMed Therapeutics Limited is currently anticipated to have valuation of 24.04 M with market capitalization of 26.17 M, debt of 448.02 K, and cash on hands of . Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the CytoMed Therapeutics fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
24.04 M | 26.17 M | 448.02 K |
CytoMed Therapeutics Investor Information
About 69.0% of the company shares are held by company insiders. The book value of CytoMed Therapeutics was currently reported as 0.88. The company recorded a loss per share of 0.22. CytoMed Therapeutics had not issued any dividends in recent years. Based on the key indicators related to CytoMed Therapeutics' liquidity, profitability, solvency, and operating efficiency, CytoMed Therapeutics Limited may be sliding down financialy. It has an above-average odds of going through some form of financial crisis next quarter.CytoMed Therapeutics Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. CytoMed Therapeutics has an asset utilization ratio of 2.35 percent. This indicates that the Company is making USD0.0235 for each dollar of assets. An increasing asset utilization means that CytoMed Therapeutics Limited is more efficient with each dollar of assets it utilizes for everyday operations.CytoMed Therapeutics Ownership Allocation
The market capitalization of CytoMed Therapeutics is USD26.17 Million. CytoMed Therapeutics Limited shows majority of its outstanding shares owned by insiders. An insider is usually defined as a corporate executive, director, member of the board or institutional investor who own at least 10% of the company's outstanding shares. 69.27 percent of CytoMed Therapeutics outstanding shares that are owned by insiders signifies that they have been buying or selling the stock in recent months in anticipation of some upcoming event. Note, that even with negative profits, if the true value of the firm is larger than the current market value, you may still be able to generate positive returns on investment in this company.CytoMed Therapeutics Profitability Analysis
The company reported the previous year's revenue of 290.56 K. Net Loss for the year was (3.13 M) with profit before overhead, payroll, taxes, and interest of 355.19 K.Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates CytoMed Therapeutics' worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in CytoMed Therapeutics and how it compares across the competition.
About CytoMed Therapeutics Valuation
The stock valuation mechanism determines CytoMed Therapeutics' current worth on a weekly basis. Our valuation model uses a comparative analysis of CytoMed Therapeutics. We calculate exposure to CytoMed Therapeutics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of CytoMed Therapeutics's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 245.1 K | 165 K | |
| Pretax Profit Margin | (9.70) | (10.18) | |
| Operating Profit Margin | (9.02) | (9.47) | |
| Net Loss | (9.70) | (10.19) | |
| Gross Profit Margin | 0.84 | 0.99 |
CytoMed Therapeutics Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 10.6 M |
CytoMed Therapeutics Current Valuation Indicators
Valuation refers to the process of determining the present value of CytoMed Therapeutics Limited and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value CytoMed we look at many different elements of the entity such as CytoMed's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as CytoMed Therapeutics, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use CytoMed Therapeutics' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes CytoMed Therapeutics' worth.Complementary Tools for CytoMed Stock analysis
When running CytoMed Therapeutics' price analysis, check to measure CytoMed Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy CytoMed Therapeutics is operating at the current time. Most of CytoMed Therapeutics' value examination focuses on studying past and present price action to predict the probability of CytoMed Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move CytoMed Therapeutics' price. Additionally, you may evaluate how the addition of CytoMed Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites |